Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA)

Hsien Tzung Liao, Chun Hsiung Chen, Wei Sheng Chen, Hui Ting Lee, Chang Youh Tsai, Chung Tei Chou

研究成果: 雜誌貢獻文章

摘要

Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are the main therapeutic agents for the treatment of peripheral arthritis in USpA. Tumor necrosis factor-α (TNF-α) has been detected in sacroiliac joints of patients with SpA. Anti-TNF-α therapy has been shown efficacious in patients with active ankylosing spondylitis (AS) and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in USpA are also limited. In those cases in which severe symptoms persist despite these treatments or when there is a severe axial involvement, biologic therapy (such as anti-TNF-α agents) represent an effective choice. In these patients, anti-TNF-α treatment raises the important possibility of blocking a shift from USpA to differentiated forms of spondyloarthritis.

原文英語
頁(從 - 到)174-176
頁數3
期刊Current Rheumatology Reviews
5
發行號3
DOIs
出版狀態已發佈 - 八月 2009

指紋

Tumor Necrosis Factor-alpha
Therapeutics
Sacroiliac Joint
Psoriatic Arthritis
Biological Therapy
Antirheumatic Agents
Ankylosing Spondylitis
Arthritis
Anti-Inflammatory Agents
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology

引用此文

Liao, H. T., Chen, C. H., Chen, W. S., Lee, H. T., Tsai, C. Y., & Chou, C. T. (2009). Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA). Current Rheumatology Reviews, 5(3), 174-176. https://doi.org/10.2174/157339709789208642

Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA). / Liao, Hsien Tzung; Chen, Chun Hsiung; Chen, Wei Sheng; Lee, Hui Ting; Tsai, Chang Youh; Chou, Chung Tei.

於: Current Rheumatology Reviews, 卷 5, 編號 3, 08.2009, p. 174-176.

研究成果: 雜誌貢獻文章

Liao, Hsien Tzung ; Chen, Chun Hsiung ; Chen, Wei Sheng ; Lee, Hui Ting ; Tsai, Chang Youh ; Chou, Chung Tei. / Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA). 於: Current Rheumatology Reviews. 2009 ; 卷 5, 編號 3. 頁 174-176.
@article{50a777d427b54a2c902756f1e91f7283,
title = "Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA)",
abstract = "Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are the main therapeutic agents for the treatment of peripheral arthritis in USpA. Tumor necrosis factor-α (TNF-α) has been detected in sacroiliac joints of patients with SpA. Anti-TNF-α therapy has been shown efficacious in patients with active ankylosing spondylitis (AS) and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in USpA are also limited. In those cases in which severe symptoms persist despite these treatments or when there is a severe axial involvement, biologic therapy (such as anti-TNF-α agents) represent an effective choice. In these patients, anti-TNF-α treatment raises the important possibility of blocking a shift from USpA to differentiated forms of spondyloarthritis.",
keywords = "Tumor necrosis factor-α (TNF-α), Undifferentiated spondyloarthritis (USpA)",
author = "Liao, {Hsien Tzung} and Chen, {Chun Hsiung} and Chen, {Wei Sheng} and Lee, {Hui Ting} and Tsai, {Chang Youh} and Chou, {Chung Tei}",
year = "2009",
month = "8",
doi = "10.2174/157339709789208642",
language = "English",
volume = "5",
pages = "174--176",
journal = "Current Rheumatology Reviews",
issn = "1573-3971",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA)

AU - Liao, Hsien Tzung

AU - Chen, Chun Hsiung

AU - Chen, Wei Sheng

AU - Lee, Hui Ting

AU - Tsai, Chang Youh

AU - Chou, Chung Tei

PY - 2009/8

Y1 - 2009/8

N2 - Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are the main therapeutic agents for the treatment of peripheral arthritis in USpA. Tumor necrosis factor-α (TNF-α) has been detected in sacroiliac joints of patients with SpA. Anti-TNF-α therapy has been shown efficacious in patients with active ankylosing spondylitis (AS) and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in USpA are also limited. In those cases in which severe symptoms persist despite these treatments or when there is a severe axial involvement, biologic therapy (such as anti-TNF-α agents) represent an effective choice. In these patients, anti-TNF-α treatment raises the important possibility of blocking a shift from USpA to differentiated forms of spondyloarthritis.

AB - Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are the main therapeutic agents for the treatment of peripheral arthritis in USpA. Tumor necrosis factor-α (TNF-α) has been detected in sacroiliac joints of patients with SpA. Anti-TNF-α therapy has been shown efficacious in patients with active ankylosing spondylitis (AS) and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in USpA are also limited. In those cases in which severe symptoms persist despite these treatments or when there is a severe axial involvement, biologic therapy (such as anti-TNF-α agents) represent an effective choice. In these patients, anti-TNF-α treatment raises the important possibility of blocking a shift from USpA to differentiated forms of spondyloarthritis.

KW - Tumor necrosis factor-α (TNF-α)

KW - Undifferentiated spondyloarthritis (USpA)

UR - http://www.scopus.com/inward/record.url?scp=70449668995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449668995&partnerID=8YFLogxK

U2 - 10.2174/157339709789208642

DO - 10.2174/157339709789208642

M3 - Article

AN - SCOPUS:70449668995

VL - 5

SP - 174

EP - 176

JO - Current Rheumatology Reviews

JF - Current Rheumatology Reviews

SN - 1573-3971

IS - 3

ER -